Analysts expect Neuronetics Inc (NASDAQ:STIM) to post earnings of ($0.40) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Neuronetics’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.41). The firm is expected to announce its next quarterly earnings report on Tuesday, November 13th.

On average, analysts expect that Neuronetics will report full-year earnings of ($2.05) per share for the current financial year, with EPS estimates ranging from ($2.29) to ($1.80). For the next fiscal year, analysts forecast that the business will post earnings of ($1.34) per share, with EPS estimates ranging from ($1.41) to ($1.27). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Neuronetics.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($30.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($29.76). The business had revenue of $13.25 million for the quarter, compared to analyst estimates of $12.20 million.

A number of brokerages recently weighed in on STIM. BTIG Research restated a “buy” rating and issued a $33.00 price objective on shares of Neuronetics in a report on Thursday, August 16th. JMP Securities lifted their price objective on shares of Neuronetics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, August 15th. Canaccord Genuity lifted their price objective on shares of Neuronetics from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, August 15th. William Blair began coverage on shares of Neuronetics in a report on Monday, July 23rd. They issued an “outperform” rating for the company. Finally, Piper Jaffray Companies began coverage on shares of Neuronetics in a report on Monday, July 23rd. They issued an “overweight” rating for the company. Five investment analysts have rated the stock with a buy rating, Neuronetics currently has a consensus rating of “Buy” and a consensus target price of $36.33.

In other Neuronetics news, insider Daniel Guthrie acquired 1,500 shares of the company’s stock in a transaction that occurred on Monday, July 2nd. The stock was purchased at an average price of $17.00 per share, for a total transaction of $25,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Wilfred E. Jaeger acquired 6,667 shares of the company’s stock in a transaction that occurred on Monday, July 2nd. The stock was acquired at an average price of $17.00 per share, with a total value of $113,339.00. The disclosure for this purchase can be found here.

Hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. purchased a new position in Neuronetics in the second quarter worth approximately $133,000. Pier Capital LLC purchased a new position in Neuronetics in the second quarter worth approximately $186,000. Granahan Investment Management Inc. MA purchased a new position in Neuronetics in the second quarter worth approximately $266,000. United Services Automobile Association purchased a new position in Neuronetics in the second quarter worth approximately $266,000. Finally, Alpine Woods Capital Investors LLC purchased a new position in Neuronetics in the second quarter worth approximately $266,000. Hedge funds and other institutional investors own 60.20% of the company’s stock.

Shares of STIM stock traded up $0.07 during trading on Friday, reaching $33.56. The company’s stock had a trading volume of 1,339 shares, compared to its average volume of 76,287. Neuronetics has a 1-year low of $23.95 and a 1-year high of $36.00.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.

Read More: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.